SCHEDULE: Goldman Sachs Discloses Esperion Therapeutics Stake

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.7% of Esperion Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• The filing is a Schedule 13G, indicating that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC are beneficial owners of Esperion Therapeutics, Inc. common stock.
• As of June 30, 2026, the aggregate amount beneficially owned is 17,222,156.04 shares, representing 6.7% of the class.
• Goldman Sachs & Co. LLC is identified as a broker-dealer and investment adviser.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to its nature as a routine disclosure of beneficial ownership rather than a strategic update or financial performance report.

Positives

• The filing confirms a significant institutional investor, Goldman Sachs, holds a substantial stake in Esperion Therapeutics.
• The disclosure is routine and indicates normal business operations for Goldman Sachs.

Negatives

• The filing does not provide any new financial performance data or strategic insights for Esperion Therapeutics.
• The nature of the filing as a 13G suggests a passive investment rather than active engagement or support for the company's strategy.

Risks

• Potential for future changes in Goldman Sachs' beneficial ownership, which could impact market liquidity or investor sentiment.
• The filing does not address any specific risks related to Esperion Therapeutics' business operations or financial health.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Esperion Therapeutics' future performance or strategy. It solely reports current beneficial ownership.

Management Comments

• The filing certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large financial institutions like Goldman Sachs, indicating their role as significant investors across various public companies. This filing confirms their passive stake in Esperion Therapeutics, a biopharmaceutical company.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional holder, which may influence investor perception.
• Management of Esperion Therapeutics: The passive nature of the holding suggests no immediate intent to influence corporate control.

Next Steps

• Goldman Sachs will continue to hold its beneficial ownership in Esperion Therapeutics, subject to market conditions and its investment strategy.
• Esperion Therapeutics will continue its operations and strategic initiatives as outlined in its other public disclosures.

Key Dates

Keywords

Esperion Therapeutics, Goldman Sachs, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Securities Exchange Act